Biote Q3 revenue $45.6M (+8.5% YoY); net income $19.6M; Adj. EBITDA $14.0M

biote Corp.

2023-Q3 EPS reported -$0.19 revenue$139,657,000

Revenue $45.6M (+8.5% YoY) driven by procedure revenue growth of 7.4% and supplement growth of 5.1%.
Net income $19.6M (43.1% margin) vs $0.5M in prior year; basic EPS $0.25 vs $0.00.
Adjusted EBITDA $14.0M (+14.7% YoY); margin 30.8% (+165bps).
Reiterated FY2023 guidance: revenue $190-200M, Adj. EBITDA $56-60M; expects lower end.
Progress in commercial trials of complementary wellness therapeutics (sexual health, weight loss, preventive).

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

biote Corp. reported the third quarter ended September 30, 2023 results: revenue $45.6 million, net income $19.6 million, EPS $0.25 per basic share. Guidance reaffirmed.

Period: the third quarter ended September 30, 2023
Revenue: $45.6 million
Net income: $19.6 million
EPS: $0.25 per basic share
Guidance: reaffirmed
Result: reported results

Exact text from the filing

for the third quarter ended September 30, 2023. Third Quarter 2023 Financial Highlights (All financial result comparisons made are against the prior year period) • Revenue of $45.6 million, an 8.5% increase • Gross profit margin of 68.9%, a 70-basis point increase • Net income of $19.6 million, representing net income margin of 43.1%, and basic earnings per share

View on SEC.gov

59 earnings releases filed in the last 30 days. Browse all earnings releases →

biote Corp. filing history →

Source: SEC EDGAR

accession 0001193125-23-272557

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.